鈣拮抗劑市場報告：2030 年趨勢、預測與競爭分析

鈣拮抗劑的趨勢與預測

預計2024年至2030年全球鈣拮抗劑市場將以5.4%的複合年成長率成長。該市場的主要驅動力是老年人口的顯著成長、多模式治療方法的普及以及心血管疾病盛行率的增加。全球鈣通道阻斷劑市場前景廣闊，高血壓、心絞痛、心律不整和肥厚性心肌病市場有機會。

鈣拮抗劑按細分市場

包含按藥物類別、給藥途徑、分銷管道、應用和地區分類的鈣通道阻斷劑的全球市場預測。

鈣拮抗劑市場洞察

Lucintel 預測，由於二氫吡啶在高血壓治療中的應用不斷增加，因此在預測期內，二氫吡啶仍將是最大的市場區隔。

高血壓仍然是該市場中最大的部分。

由於心血管疾病的高發生率和人口老化，北美在預測期內將繼續成為最大的市場。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球鈣通道阻斷劑市場預計將以5.4%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 此市場的主要驅動力是老年人口的顯著成長、多模式治療方法的增加以及心血管疾病盛行率的增加。

Q3.市場的主要細分市場是：

A3. 鈣通道阻斷劑市場前景廣闊，高血壓、心絞痛、心律不整和肥厚性心肌病市場充滿機會。

Q4.市場的主要企業是：

A4. 生產鈣拮抗劑的主要企業如下：

• Pfizer
• Teva Pharmaceutical Industries
• Bausch Health Company
• Novartis
• AstraZeneca
• Merck
• GSK
• Bayer
• Sun Pharmaceutical Industries
• Daiichi Sankyo

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預測，由於二氫吡啶類藥物在高血壓治療中的應用不斷增加，因此在預測期內，二氫吡啶類藥物將繼續成為最大的市場區隔。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 由於心血管疾病的高發生率和人口老化，北美在預測期內仍將是最大的市場。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球鈣拮抗劑市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球鈣拮抗劑市場趨勢（2018-2023）與預測（2024-2030）
• 全球鈣拮抗劑市場：依藥物類別
  • 苯烷基胺
  • 苯並氮平
  • 二氫吡啶
• 全球鈣通道阻斷劑市場：依給藥途徑
  • 口服
  • 胃腸外的
• 全球鈣拮抗劑市場：按通路
  • 醫院藥房
  • 零售藥房
  • 網路藥房
• 全球鈣拮抗劑市場：依應用分類
  • 高血壓
  • 心絞痛
  • 心律不整
  • 肥厚型心肌病
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 按地區分類的全球鈣通道阻斷劑市場
• 北美鈣通道阻斷劑市場
• 歐洲鈣通道阻斷劑市場
• 亞太地區鈣拮抗劑市場
• 其他區域鈣拮抗劑市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按藥物類別分類的全球鈣拮抗劑市場成長機會
  • 按途徑的全球鈣拮抗劑市場成長機會
  • 全球鈣拮抗劑市場成長機會（按分銷管道）
  • 鈣通道阻斷劑的全球市場成長機會（按應用）
  • 全球鈣拮抗劑市場成長機會（按地區）
• 全球鈣拮抗劑市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球鈣拮抗劑市場產能擴張
  • 全球鈣通道阻斷劑市場的合併、收購與合資企業
  • 認證和許可

第7章主要企業概況

• Pfizer
• Teva Pharmaceutical Industries
• Bausch Health Company
• Novartis
• AstraZeneca
• Merck
• GSK
• Bayer
• Sun Pharmaceutical Industries
• Daiichi Sankyo

Calcium Channel Blockers Trends and Forecast

The future of the global calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets. The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches, and growing prevalence rate of cardiovascular diseases.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Calcium Channel Blockers by Segment

The study includes a forecast for the global calcium channel blockers by drug class, route of administration, distribution channel, application, and region.

Calcium Channel Blockers Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Phenylalkylamine
• Benzothizepine
• Dihydropyridine

Calcium Channel Blockers Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Oral
• Parenteral

Calcium Channel Blockers Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Calcium Channel Blockers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hypertension
• Angina
• Arrhythmia
• Hypertrophic Cardiomyopathy
• Others

Calcium Channel Blockers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Calcium Channel Blockers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies calcium channel blockers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the calcium channel blockers companies profiled in this report include-

• Pfizer
• Teva Pharmaceutical Industries
• Bausch Health Company
• Novartis
• AstraZeneca
• Merck
• GSK
• Bayer
• Sun Pharmaceutical Industries
• Daiichi Sankyo

Calcium Channel Blockers Market Insights

Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Within this market, hypertension will remain the largest segment.

North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Features of the Global Calcium Channel Blockers Market

Market Size Estimates: Calcium channel blockers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Calcium channel blockers market size by various segments, such as by drug class, route of administration, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Calcium channel blockers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administration, distribution channels, application, and regions for the calcium channel blockers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the calcium channel blockers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for calcium channel blockers market?

Answer: The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the calcium channel blockers market?

Answer: The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches and growing prevalence rate of cardiovascular diseases.

Q3. What are the major segments for calcium channel blockers market?

Answer: The future of the calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets.

Q4. Who are the key calcium channel blockers market companies?

Answer: Some of the key calcium channel blockers companies are as follows:

• Pfizer
• Teva Pharmaceutical Industries
• Bausch Health Company
• Novartis
• AstraZeneca
• Merck
• GSK
• Bayer
• Sun Pharmaceutical Industries
• Daiichi Sankyo

Q5. Which calcium channel blockers market segment will be the largest in future?

Answer: Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Q6. In calcium channel blockers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the calcium channel blockers market by drug class (phenylalkylamine, benzothizepine, and dihydropyridine), route of administration (oral and parenteral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (hypertension, angina, arrhythmia, hypertrophic cardiomyopathy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Calcium Channel Blockers Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Calcium Channel Blockers Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Calcium Channel Blockers Market by Drug Class
  • 3.3.1: Phenylalkylamine
  • 3.3.2: Benzothizepine
  • 3.3.3: Dihydropyridine
• 3.4: Global Calcium Channel Blockers Market by Route of Administration
  • 3.4.1: Oral
  • 3.4.2: Parenteral
• 3.5: Global Calcium Channel Blockers Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies
• 3.6: Global Calcium Channel Blockers Market by Application
  • 3.6.1: Hypertension
  • 3.6.2: Angina
  • 3.6.3: Arrhythmia
  • 3.6.4: Hypertrophic Cardiomyopathy
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Calcium Channel Blockers Market by Region
• 4.2: North American Calcium Channel Blockers Market
  • 4.2.1: North American Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
  • 4.2.2: North American Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
• 4.3: European Calcium Channel Blockers Market
  • 4.3.1: European Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
  • 4.3.2: European Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
• 4.4: APAC Calcium Channel Blockers Market
  • 4.4.1: APAC Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
  • 4.4.2: APAC Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
• 4.5: ROW Calcium Channel Blockers Market
  • 4.5.1: ROW Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
  • 4.5.2: ROW Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Calcium Channel Blockers Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Calcium Channel Blockers Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Calcium Channel Blockers Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Calcium Channel Blockers Market by Application
  • 6.1.5: Growth Opportunities for the Global Calcium Channel Blockers Market by Region
• 6.2: Emerging Trends in the Global Calcium Channel Blockers Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Calcium Channel Blockers Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Calcium Channel Blockers Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Teva Pharmaceutical Industries
• 7.3: Bausch Health Company
• 7.4: Novartis
• 7.5: AstraZeneca
• 7.6: Merck
• 7.7: GSK
• 7.8: Bayer
• 7.9: Sun Pharmaceutical Industries
• 7.10: Daiichi Sankyo